To Download a copy of the presentation click here.
To Download a copy of the Q&A Responses here.
*This call was funded by a cooperative agreement with the Centers for Disease Control and Prevention (grant number NU50CK000574). The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this call does not necessarily represent the policy of CDC or HHS, and should not be considered an endorsement by the Federal Government.
Topic: Updates & Emerging Issues on COVID-19 and Monkeypox
Moderator:
Dana S. Wollins, DrPH, MGC
Vice President, Clinical Affairs & Practice Guidelines, IDSA
Topics and Featured Experts
COVID-19: Situation Update, Emerging Variants & Implications for Therapeutics:
Pragna Patel, MD, MPH
Captain, U.S. Public Health Service
Chief Medical Officer (acting)
Coronavirus and Other Respiratory Diseases Division (proposed)
National Center for Immunization and Respiratory Diseases
U.S. Centers for Disease Control & Prevention
Meghan E. Pennini, PhD
Therapeutics Director
Administration for Strategic Preparedness and Response
U.S. Department of Health and Human Services
Monkeypox: Clinical Characteristics and Treatment Options for Severe Disease:
Introductory Remarks:
Agam Rao, MD, MPH
Poxvirus SME
CDC Multinational Monkeypox Response
U.S. Centers for Disease Control and Prevention
Case Presentations:
Severe Monkeypox in a Patient With Newly Diagnosed HIV
Robert Atmar, MD, FIDSA
Professor, Medicine-Infectious Diseases, Baylor College of Medicine
Chief, Infectious Diseases; Ben Taub Hospital
Encephalitis in a Patient With Severe Monkeypox
Matt Copeland, MD
Assistant Professor
Georgetown University Medical Center
Ocular Monkeypox
Vivian Huang, MD, MPH
Assistant Medical Director
Office of Epidemiology and Data Services
Maricopa County Department of Public Health
Nelson Nicolasora, MD
Division of Infectious Diseases
Banner-University Medical Center Phoenix
